118 related articles for article (PubMed ID: 2575687)
1. [Current aspects of stress ulcer prevention].
Laggner AN
Krankenpfl J; 1989 Dec; 27(12):16-8. PubMed ID: 2575687
[No Abstract] [Full Text] [Related]
2. [Current aspects of course treatment and secondary prevention of peptic ulcer].
Ryss ES
Klin Med (Mosk); 1990 Apr; 68(4):134-42. PubMed ID: 1973467
[No Abstract] [Full Text] [Related]
3. Gastrointestinal prophylaxis in critically ill patients.
Singh H; Houy TL; Singh N; Sekhon S
Crit Care Nurs Q; 2008; 31(4):291-301. PubMed ID: 18815475
[TBL] [Abstract][Full Text] [Related]
4. Ranitidine and gastrointestinal bleeding in intensive care. Should prophylaxis against stress ulcer be abondoned for patients in intensive care.
Preiser JC
BMJ; 2001 Apr; 322(7292):995. PubMed ID: 11339222
[No Abstract] [Full Text] [Related]
5. Famotidine to prevent peptic ulcer caused by NSAIDs.
Singh G; Fries JF
N Engl J Med; 1996 Oct; 335(17):1322; author reply 1322-3. PubMed ID: 8992334
[No Abstract] [Full Text] [Related]
6. When should stress ulcer prophylaxis be used in the ICU?
Quenot JP; Thiery N; Barbar S
Curr Opin Crit Care; 2009 Apr; 15(2):139-43. PubMed ID: 19578324
[TBL] [Abstract][Full Text] [Related]
7. Prevention of NSAID-induced GI mucosal injury.
Gerritz S; Newton WP
J Fam Pract; 1997 Feb; 44(2):130-1. PubMed ID: 9040509
[No Abstract] [Full Text] [Related]
8. [Prevention of ulcer disease].
Loizeau E
Schweiz Med Wochenschr; 1986 Oct; 116(40):1371-4. PubMed ID: 2877491
[TBL] [Abstract][Full Text] [Related]
9. [Therapy of peptic ulcer. H2 receptor blockers].
Domschke W
Verh Dtsch Ges Inn Med; 1988; 94():272-5. PubMed ID: 2905101
[No Abstract] [Full Text] [Related]
10. On the need for observational studies to design and interpret randomized trials in ICU patients: a case study in stress ulcer prophylaxis.
Cook D; Heyland D; Marshall J;
Intensive Care Med; 2001 Feb; 27(2):347-54. PubMed ID: 11396278
[No Abstract] [Full Text] [Related]
11. [Antagonists of the histamine H2 receptors in the stomach].
Landa L
Gac Med Mex; 1981 Dec; 117(12):472-4. PubMed ID: 6123460
[No Abstract] [Full Text] [Related]
12. [Current principles of prevention of acute postoperative lesions of the gastrointestinal tract].
Iaremchuk AIa; Zotov AS
Vestn Khir Im I I Grek; 2001; 160(3):101-4. PubMed ID: 11517776
[No Abstract] [Full Text] [Related]
13. [Current medical treatment of ulcer disease].
Walan A
Lakartidningen; 1984 Apr; 81(17):1727-33. PubMed ID: 6144825
[No Abstract] [Full Text] [Related]
14. [Current locally acting agents in the treatment of peptic ulcer].
Ryss ES
Klin Med (Mosk); 1986 Aug; 64(8):18-27. PubMed ID: 2878103
[No Abstract] [Full Text] [Related]
15. [Prevention of stress ulcer: an essentially necessary measure in intensive care patients? Arguments pro].
Gyr NE; Meier R
Z Gastroenterol; 1991 Jan; 29 Suppl 1():4-6; discussion 9. PubMed ID: 1683734
[No Abstract] [Full Text] [Related]
16. [Clinical aspects of Kvamatel (famotidine) administration].
Golochevskaia VS
Klin Med (Mosk); 1996; 74(1):45-7. PubMed ID: 8649009
[No Abstract] [Full Text] [Related]
17. [Mechanism of action and therapeutic effectiveness of histamine H2 receptor blockaders in peptic ulcer].
Glubochenko VG; Shcherbak VV
Vrach Delo; 1985 Feb; (2):13-5. PubMed ID: 2859701
[No Abstract] [Full Text] [Related]
18. [Current trends in medical therapy of gastroduodenal ulcer].
Grassi M; Fraioli A; Messina B
Clin Ter; 1987 Dec; 123(6):475-86. PubMed ID: 2902954
[No Abstract] [Full Text] [Related]
19. [What is the role of H2 receptor blockers today in ulcer therapy?].
Creutzfeldt W
Internist (Berl); 1996 Sep; 37(9):937-8. PubMed ID: 8964690
[No Abstract] [Full Text] [Related]
20. [Pathophysiologic bases of the pharmacotherapy of peptic ulcer].
Grigor'ev PIa; Isakov VA; Vasil'eva ZI
Klin Med (Mosk); 1988 Nov; 66(11):19-27. PubMed ID: 2907071
[No Abstract] [Full Text] [Related]
[Next] [New Search]
